San Carlos, CA, United States of America

Wouter Korver

This inventor holds 2 USPTO granted patents. Top assignee: Allakos Inc.. Active years: 2023-2024.


% Patents Active = 100.0

Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Wouter Korver: Innovator in Cancer Treatment

Introduction

Wouter Korver is a notable inventor based in San Carlos, CA (US). He has made significant contributions to the field of cancer treatment through his innovative work on anti-Siglec-7 antibodies. With a total of 2 patents, Korver is dedicated to advancing medical science and improving patient outcomes.

Latest Patents

Korver's latest patents include "Anti-Siglec-7 antibodies having reduced effector function" and "Anti-Siglec-7 antibodies for the treatment of cancer." The first patent provides methods and compositions for treating cancer using anti-Siglec-7 antibodies that have reduced effector function. The second patent outlines methods and compositions for the treatment of cancer using anti-Siglec-7 antibodies.

Career Highlights

Wouter Korver is currently associated with Allakos Inc., a company focused on developing innovative therapies for serious diseases. His work at Allakos has positioned him as a key player in the biotechnology sector, particularly in the development of cancer treatments.

Collaborations

Korver collaborates with talented professionals in his field, including Nenad Tomasevic and Christopher Robert Bebbington. These collaborations enhance the research and development efforts at Allakos Inc., contributing to the advancement of cancer therapies.

Conclusion

Wouter Korver's contributions to cancer treatment through his patents and work at Allakos Inc. highlight his commitment to innovation in the medical field. His research on anti-Siglec-7 antibodies represents a significant step forward in the fight against cancer.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…